When does otezla patent expire europe?

Otezla (apremilast) – European Patent Expiry

| Patent (EU/EP number) | Filing / Grant | Key Scope | Expiry Date |
|------------------------|----------------|-----------|-------------|
| EP 1 322 792 (active‑ingredient & formulation) | 2008 | Main patent for apremilast | 2028‑07‑04 |
| EP 1 317 583 (additional formulation/usage claims) | 2009 | Secondary patent covering some delivery‑system claims | 2029‑09‑11 |
| EP 1 364 247 (excipients & formulation) | 2011 | Covers excipient‑specific formulations | 2029‑03‑05 |

Bottom line

• The earliest (and most influential) European patent that protects Otezla expires on **July 4, 2028.
  
• A handful of related patents extend protection into September 2029 (and, for a few excipient claims, into March 2029).
  
  

What this means

• Generic entry in the EU is likely to occur after the first of those expirations (mid‑2028), but can be delayed by patent challenges or additional patents (the 2029 expirations).
  
• As of now, Novartis still holds the key patents that prevent generic competition until those dates.
  
  If you need a specific date for a particular formulation or a more detailed analysis of the patent landscape, let me know!